282 related articles for article (PubMed ID: 37641650)
1. A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity.
Kim A; Nguyen J; Babaei M; Kim A; Geller DH; Vidmar AP
Adolesc Health Med Ther; 2023; 14():125-140. PubMed ID: 37641650
[TBL] [Abstract][Full Text] [Related]
2. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
3. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
Sweeting AN; Tabet E; Caterson ID; Markovic TP
Diabetes Metab Syndr Obes; 2014; 7():35-44. PubMed ID: 24550678
[TBL] [Abstract][Full Text] [Related]
4. Phentermine and topiramate for the management of obesity: a review.
Cosentino G; Conrad AO; Uwaifo GI
Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
[TBL] [Abstract][Full Text] [Related]
5. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
8. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
[TBL] [Abstract][Full Text] [Related]
10. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Garvey WT
Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
[TBL] [Abstract][Full Text] [Related]
12. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
13. The Potential Role of Combination Pharmacotherapy to Improve Outcomes of Pediatric Obesity: A Case Report and Discussion.
Fox CK; Kelly AS
Front Pediatr; 2018; 6():361. PubMed ID: 30542644
[TBL] [Abstract][Full Text] [Related]
14. Phentermine/Topiramate: Pediatric First Approval.
Dhillon S
Paediatr Drugs; 2022 Nov; 24(6):715-720. PubMed ID: 36059008
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL; Adler S; Dalai SS; Bentley JP; Toyama H; Pajarito S; Najarian T
Int J Eat Disord; 2020 Feb; 53(2):266-277. PubMed ID: 31721257
[TBL] [Abstract][Full Text] [Related]
16. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
17. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
18. Current and future state of pharmacological management of pediatric obesity.
Fox CK; Kelly AS; Reilly JL; Theis-Mahon N; Raatz SJ
Int J Obes (Lond); 2024 Feb; ():. PubMed ID: 38321079
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
